Domain Therapeutics inks I-O deal with Explicyte

French drug developer Domain Therapeutics and Explicyte, an expert in the field of immune-oncology (I-O) and innovative target identification through multiparametric approaches, today announced the signing of a partnership agreement.

The two companies will combine their expertise to identify G protein-coupled receptors (GPCR) targets and associated biomarkers to discover and develop breakthrough therapeutic programs for I-O. Financial terms of the collaboration are not disclosed.

Contract Research Organization (CRO) Explicyte has generated proprietary RNA-sequencing-based data from preclinical syngeneic tumor models, enabling it to interrogate and decipher transcriptomics from the tumor and its microenvironment, and to correlate data to the response to prototypical immune checkpoint inhibitors. Data analysis allowed for differential gene expression profiling between animals that respond, or not, to immune checkpoint blockade. Domain Therapeutics has secured exclusive access to Explicyte’s GPCR-related data.